In line with this understanding, tumor antigen–independent CD40 agonists, such as anti-CD40 antibodies, have been explored in therapeutic strategies to boost tumor immunity by, e.g., overcoming the tumor-induced immunosuppression (7–9). Here, CD40 is linked to neoplasm.